Liraglutide 2.4mg Weight Loss Average: What the Evidence Shows
The average weight loss on liraglutide 2.4mg is approximately 6.3 kg (about 14 lbs) over 20 weeks, according to the pivotal dose-ranging study published in The Lancet. This places the 2.4mg dose squarely in the clinically meaningful range, making it a viable option for patients who respond well here. We will break down the data, compare it to other doses, and explain what factors shape your individual outcome.
The Key Study: Astrup et al. Dose-Ranging Trial
The most direct evidence for liraglutide 2.4mg weight loss comes from the 2009 dose-ranging study led by Astrup and colleagues. This randomized, double-blind trial enrolled 564 adults with BMI between 30 and 40 and tested four liraglutide doses against placebo and orlistat.
| Treatment | Mean Weight Loss (kg) | Mean Weight Loss (%) | Patients Losing 5%+ Body Weight |
|---|---|---|---|
| Placebo | 2.8 kg | 2.8% | 30% |
| Orlistat 120mg 3x daily | 4.1 kg | 4.1% | 44% |
| Liraglutide 1.2mg | 4.8 kg | 4.8% | 46% |
| Liraglutide 1.8mg | 5.5 kg | 5.5% | 52% |
| Liraglutide 2.4mg | 6.3 kg | 6.3% | 56% |
| Liraglutide 3.0mg | 7.2 kg | 7.2% | 61% |
At 2.4mg, over half of patients crossed the clinically significant 5% weight loss threshold within just 20 weeks. That is meaningful because a 5% reduction has been shown to improve blood pressure, triglycerides, fasting glucose, and overall cardiovascular risk.
How 2.4mg Compares Within the Dose Range
The dose-response curve for liraglutide shows a clear, nearly linear relationship between dose and weight loss up to 3.0mg. Going from 1.8mg to 2.4mg adds approximately 0.8 kg of additional weight loss. Going from 2.4mg to 3.0mg adds another 0.9 kg.
In percentage terms, liraglutide 2.4mg delivers about 87% of the weight loss achieved at the full 3.0mg dose. For patients who find 2.4mg more tolerable, that trade-off is often worth it. liraglutide 3.0mg weight loss average
Projecting Longer-Term Results
The Astrup dose-ranging study lasted 20 weeks. The larger SCALE trials, which used 3.0mg, ran for 56 weeks and showed continued weight loss beyond the 20-week mark, though the rate slowed after months 4 to 5.
Extrapolating from this pattern, patients maintaining liraglutide 2.4mg beyond 20 weeks can reasonably expect:
- Additional weight loss of 1 to 3 kg between weeks 20 and 40
- A plateau phase beginning around months 5 to 7
- Total estimated weight loss of 7 to 9% of baseline body weight by 12 months
Real-World vs. Clinical Trial Results
Clinical trial participants receive structured dietary counseling, regular monitoring, and support that typical patients may not have. Real-world studies of liraglutide generally show slightly lower average weight loss than trial data, typically 4 to 6% at the 3.0mg dose over 6 to 12 months.
For the 2.4mg dose, real-world results would likely fall in the 3 to 5% range at 6 months. Patients who pair the medication with consistent dietary improvements and regular exercise typically outperform these averages.
Who Tends to Lose More at 2.4mg
Research has identified several characteristics associated with better response to GLP-1 therapy:
- Higher baseline BMI: Patients starting at BMI 35+ often see larger absolute weight losses
- Prediabetes or early diabetes: The insulin-sensitizing effects of liraglutide provide an extra metabolic boost in this population
- Early responders: Patients who lose 4%+ of body weight in the first 12 weeks tend to continue losing. This early response is one of the strongest predictors of long-term success.
- Structured nutrition plan: Working with a dietitian or following a calorie-controlled plan significantly improves outcomes
- Consistent exercise: 150+ minutes of moderate-intensity activity per week
Frequently Asked Questions
Is 6.3 kg of weight loss enough to improve my health?
For most patients, yes. The cardiometabolic benefits of weight loss begin at the 3 to 5% threshold and increase progressively. A 6.3% loss improves blood pressure, lipid profiles, insulin sensitivity, and inflammation markers in the majority of patients studied. health benefits of GLP-1 weight loss
Should I increase to 3.0mg to lose more weight?
If you are tolerating 2.4mg well and want additional weight loss, advancing to 3.0mg typically produces another 1 to 2 lbs of loss. Discuss with your physician whether the potential increase in side effects justifies the additional benefit for your specific situation.
What if I have not lost 5% of my body weight after 12 weeks at 2.4mg?
This is the standard evaluation point for GLP-1 weight loss medications. If results are below this benchmark, your physician will consider whether to increase the dose, switch medications, or address lifestyle factors that may be limiting your response.
How does liraglutide 2.4mg compare to semaglutide or tirzepatide?
Semaglutide 2.4mg weekly (Wegovy) produces approximately 15% weight loss at 68 weeks. Tirzepatide at maximum dose produces approximately 20 to 22% weight loss. Liraglutide 2.4mg daily produces roughly 6 to 7%. The newer agents are more potent for weight loss, but liraglutide remains a proven option with long-term safety data and may be preferred for specific patient profiles.
Results-Driven Treatment at FormBlends
At FormBlends, we track your weight, metabolic markers, and overall well-being at every visit. Whether 2.4mg is delivering the results you need or an adjustment is warranted, our physicians make data-driven decisions tailored to you.
Want to know how your results compare? Schedule a consultation with a FormBlends physician today.